This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Hypoxic Ischemic Encephalopathy
and you are
under 12
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to determine the efficacy of high dose Erythropoietin to improve survival and neurologic outcome in asphyxiated term newborn undergoing cooling.

Provided treatments

  • Drug: erythropoietin Beta
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01732146. The sponsor of the trial is Assistance Publique - Hôpitaux de Paris and it is looking for 120 volunteers for the current phase.
Official trial title:
Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelae in Term Newborn